Catalyst Event

Cogent Biosciences Inc (COGT) · Other

From KEDI U.S. Next Tech TOP10 Index (KUNTT10)

5/30/2026, 12:00:00 AM

OtherSentiment: Positive

Presentation of detailed positive data from the PEAK Phase 3 trial for bezuclastinib in GIST at the 2026 ASCO Annual Meeting on 2026-05-30, showing a median Progression-Free Survival of 16.5 months vs 9.2 months for the control arm; high impact (≥10%) expected due to pivotal trial results, scheduled.

Korean Translation

2026년 5월 30일 ASCO 연례회의에서 위장관기질종양(GIST) 대상 베주클라스티닙 PEAK 3상 상세 데이터 발표 예정; 중추적 임상 결과에 따른 10% 이상의 주가 영향이 예상됨.

Related Recent Events

View Full Timeline